A new way to infiltrate (and destroy) some of the deadliest drug-resistant bugs
About four years ago, Ruben Tommasi, the gregarious scientific chief of antibiotics startup Entasis, walked into a meeting with his top chemist and top biologist to chew over another batch of unchanging results.
“It felt like we were running the same experiment over and over,” Tommasi told Endpoints News. “We had all sort of come to that point in time where we felt like we were banging our heads against the wall.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 124,100+ biopharma pros reading Endpoints daily — and it's free.